Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVB-2640 in Resectable Colon Cancer
NCT02980029Phase 1Terminated
- Start
- Oct 2017
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in colon cancer comparing TVB-2640 with Placebo (2 arms). Primary endpoints: Malonyl carnitine levels up to 56 Days and Tripalmitin levels up to 56 Days. Started Oct 2017; status: terminated.
02
Drugs
denifanstat
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02980029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980029.